Eli Lilly reported $19.3 billion in revenue for Q4 and is expanding its GLP-1 franchise into immunology and inflammation. Ongoing trials target asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn's disease and ulcerative colitis.
Original title: “Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I”